Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GH

GH - Guardant Health Inc Stock Price, Fair Value and News

$109.79-4.80 (-4.19%)
Market Closed

21/100

GH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

21/100

GH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$91.8

Target 3M

$103.28

Target 6M

$97.54

GH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GH Price Action

Last 7 days

-5.1%

Last 30 days

8.3%

Last 90 days

18.8%

Trailing 12 Months

127.5%

GH RSI Chart

GH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GH Valuation

Market Cap

13.8B

Price/Earnings (Trailing)

-34.7

Price/Sales (Trailing)

15.33

EV/EBITDA

-40.21

Price/Free Cashflow

-52.77

GH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$91.8

Target 3M

$103.28

Target 6M

$97.54

GH Fundamentals

GH Revenue

Revenue (TTM)

902.6M

Rev. Growth (Yr)

38.5%

Rev. Growth (Qtr)

14.27%

GH Earnings

Earnings (TTM)

-398.8M

Earnings Growth (Yr)

13.95%

Earnings Growth (Qtr)

7.18%

GH Profitability

EBT Margin

-44.05%

Return on Equity

112.5%

Return on Assets

-31.23%

Free Cashflow Yield

-1.9%

GH Investor Care

Shares Dilution (1Y)

2.01%

Diluted EPS (TTM)

-3.21

GH Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025774.0M828.8M902.6M0
2024603.7M643.8M692.3M739.0M
2023482.2M510.2M535.8M563.9M
2022391.1M408.1M430.8M449.5M
2021297.9M323.7M343.9M373.7M
2020245.2M257.6M271.3M286.7M
2019110.6M145.2M184.4M214.4M
201860.0M70.2M80.4M90.6M
20170037.5M49.8M
201600025.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Guardant Health Inc

GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
 CEO
 WEBSITEhttps://guardanthealth.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES1793

Guardant Health Inc Frequently Asked Questions

GH is the stock ticker symbol of Guardant Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Guardant Health Inc is 13.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check GH's fair value in chart for subscribers.

The fair value guage provides a quick view whether GH is over valued or under valued. Whether Guardant Health Inc is cheap or expensive depends on the assumptions which impact Guardant Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GH.

As of Wed Jan 28 2026, GH's PE ratio (Price to Earnings) is -34.7 and Price to Sales (PS) ratio is 15.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GH PE ratio will change depending on the future growth rate expectations of investors.